Title:
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer (COMPPARE)
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Title:
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Indication:
Multiple Myeloma
Location:
Texas Oncology-Canton
Phase: Ib/II
Title:
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II/III
Title:
Phase Ib study of gevokizumab in combination with standard of care anti-cancer therapies in patients with metastatic colorectal cancer, gastroesophageal cancer and renal cell carcinoma
Indication:
GI
Location:
Texas Oncology-Canton
Phase: Ib
Title:
A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Title:
A Phase 1, Multi-center, Open-label, Single-arm, Dose escalation, First-in-human Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 Monotherapy in Patients with Locally Advanced/Metastatic Solid Tumours
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Title:
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
STAR PH 2 Enfortumab in Urothelial Pts-Cohort L
View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Bladder Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Bladder Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph2 Sub Mosunetuzumab B-cell malig
View
Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
Indication:
Blood Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA
View
Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph 3 BYL719 + nabpax TNBC PIK3CA
View
Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph3 GDC-9545+ Palbo +/- Letro HER2- BC
View
Description: (BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1a/1b LY3484356 Abem ER+ HER2-
View
Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Registry study with Breast Cancer Index
View
Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: IV
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4)
View
Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
View
Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph3 Gem Carbo BC Preserve 2
View
Description: A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06)
View
Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA
View
Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
PH3 Enobosarm AR+ER+HER2- Fulv
View
Description: (V3002401) ARTEST - A Randomized Crossover Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining ≥ 40% Who Have Shown Previous Disease Progression onBeen Previously Treated With a Nonsteroidal Aromatase Inhibitor FulvestrantSERD and CDK 4/6 inhibitorAromatase Inhibitor Fulvestrant and CDK 4/6 inhibitor
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC
View
Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph2 Trila Sacit Gove TNBC
View
Description: A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Breast Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Cervical Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
BESPOKE ctDNA Colorectal Cancer
View
Description: BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer (20-041-NCP)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Title:
Ph1b/2 Surufatinib + Tislelizumab ST
View
Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1b AMG 510 MVASI Combo KRAS CRC
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b AMG 510 + TNO155 KRAS p.G12C Solids
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib (AMG 510) in Combination with TNO155 in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol N)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Colon Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1a/1b LY3484356 Abem ER+ HER2-
View
Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
INCMGA00012 Endo Cancer
View
Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph 3 Pemb v Plat Dbl dMMR Endo Carcinoma
View
Description: A Phase 3 Randomized Open-label Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (MK-3475-C93/GOG-3064)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
PH2/3 Tuca Trast vs Placebo HER2+ GEC
View
Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Canton
Phase: II/III
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph2 AKT Pac vs Ova fall and Peri
View
Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
PH2/3 Tuca Trast vs Placebo HER2+ GEC
View
Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)
Indication:
Gastric Cancer
Location:
Texas Oncology-Canton
Phase: II/III
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Gastric Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b/2 Surufatinib + Tislelizumab ST
View
Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)
Indication:
Gastric Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Gastric Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
View
Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Hematologic
Location:
Texas Oncology-Canton
Phase: II
Title:
PATHFINDER 2 Early Detection Test
View
Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)
Indication:
Hematologic
Location:
Texas Oncology-Canton
Phase: IV
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Canton
Phase: II
Title:
PH3 Ven+G vs FCR/BR in Fit untreated CLL
View
Description: A PROSPECTIVE OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)
Indication:
Leukemia
Location:
Texas Oncology-Canton
Phase: III
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Leukemia
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph3b ABL001 in CML-CP +/-T315i
View
Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)
Indication:
Leukemia
Location:
Texas Oncology-Canton
Phase: III/IV
Title:
Ph1b/2 APG-115 Azacitidine r/r AML CMML MDS
View
Description: A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML CMML or MDS (APG115AU101)
Indication:
Leukemia
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph3 Ascim vs PC TKI new dx Ph+ CML
View
Description: A phase III multi-center open-label randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12301)
Indication:
Leukemia
Location:
Texas Oncology-Canton
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph2 Nap r/r NSCLC
View
Description: NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR PH3 JNJ-61186372 Peme EGFR NSCLC
View
Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph2 MRTX849 Pembro NSCLC KRAS
View
Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b AMG 510 in Combo NSCLC KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol F)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b Sotora NSCLC KRAS p.G12C Brain Met
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b AMG510 + Pembro NSCLC KRAS G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1b/2 Surufatinib + Tislelizumab ST
View
Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph2 Tomivosertib+Anti-PD-L1 NSCLC
View
Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C
View
Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Biomarker status NSCLC
View
Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1b AMG 510 + TNO155 KRAS p.G12C Solids
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib (AMG 510) in Combination with TNO155 in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol N)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC
View
Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)
Indication:
Lung Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
STAR BV in pts w/1L cHL or PTCL
View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: I
Title:
LTFU T-Cells
View
Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II/III
Title:
Ph3 Tafa+ Lena R-CHOP B-Cell Lymp
View
Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1b/2 TAK-981 + Ritux r/r CD20+ NHL
View
Description: Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma (TAK-981-1501)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: I/II
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph3 LOXO-305 vs PC of BTK in MCL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph2 Sub Mosunetuzumab B-cell malig
View
Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph2 Lonca-R DLBCL
View
Description: A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9/ ADCT-402-203)
Indication:
Lymphomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Melanoma
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Melanoma
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph 1/2 ASTX727 Lower Risk MDS
View
Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1b/2 APG-115 Azacitidine r/r AML CMML MDS
View
Description: A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML CMML or MDS (APG115AU101)
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-Canton
Phase: I/II
Title:
STAR Ph3 Navi Ruxo Myelofibrosis
View
Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
Indication:
Myelofibrosis
Location:
Texas Oncology-Canton
Phase: III
Title:
STAR Ph2 Selinexor vs PC MF
View
Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)
Indication:
Myelofibrosis
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 SEA-BCMA R/R MM
View
Description: A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma (SGNBCMA-001)
Indication:
Myelomas
Location:
Texas Oncology-Canton
Phase: I
Title:
PH3 Dara/Len vs Len NDMM
View
Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)
Indication:
Myelomas
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph2 Dara Lena Dexa (DRd) MM I
View
Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)
Indication:
Myelomas
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1b/2 Surufatinib + Tislelizumab ST
View
Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-Canton
Phase: I/II
Title:
PH3 Alpe BYL719 Olap BRCA OC
View
Description: EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph2 AKT Pac vs Ova fall and Peri
View
Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph2 VS-6766 Fak-Inhib LGSOC
View
Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1b/2 XMT-1536 ST NaPi2b
View
Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph2 AKT Pac vs Ova fall and Peri
View
Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
Biomarker DNA Defect Men Prostate
View
Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: III
Title:
Ph2 BMS986218 + Niv combo Doce met CRPC
View
Description: A Phase 2 Open-label Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer (CA022-009)
Indication:
Prostate Cancer
Location:
Texas Oncology-Canton
Phase: II
Title:
BESPOKE ctDNA Colorectal Cancer
View
Description: BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer (20-041-NCP)
Indication:
Rectal Cancer
Location:
Texas Oncology-Canton
Title:
Ph1b/2 Surufatinib + Tislelizumab ST
View
Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)
Indication:
Rectal Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Renal Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1 FIH TP-1287 Solid tumor
View
Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)
Indication:
Sarcoma
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b/2 Surufatinib + Tislelizumab ST
View
Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)
Indication:
Sarcoma
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Skin Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph1/2 FIH BMS-986249 + Nivo Solid Tumor
View
Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1 FIH TP-1287 Solid tumor
View
Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C
View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Ph2 Tumor-Agnostic Precision TAPISTRY
View
Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: II
Title:
STAR Ph2 Seribantumab NRG1 Fusion+ ST
View
Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b AMG 510 + Palboc ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph1b/2 Surufatinib + Tislelizumab ST
View
Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I/II
Title:
PATHFINDER 2 Early Detection Test
View
Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: IV
Title:
Ph1b AMG 510 + TNO155 KRAS p.G12C Solids
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib (AMG 510) in Combination with TNO155 in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol N)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: II
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Solid Tumors
Location:
Texas Oncology-Canton
Phase: I/II
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: I/II
Title:
STAR PH 2 Enfortumab in Urothelial Pts-Cohort L
View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Canton
Phase: I/II